Clonality detection of expanded T-cell populations in patients with multiple myeloma.

D. Sze

DOI: https://doi.org/10.1385/1-59259-916-8:257

Abstract:

What problem does this paper attempt to address?

Analysis of Tumor Specific Immunoglobulin Gene Rearrangement in Peripheral Blood B-cells of Multiple Myeloma Patients by a PCR-SSCP Method.

SL Wu,LH Wang,Y Wang,P Zhu,GL Xie

1997-01-01

Abstract:OBJECTIVE:To analyze the clonal relationship between lymphocytes in peripheral blood (PB) and myeloma cell in bone marrow (BM) for proving the existence of circulating tumor cells in multiple myeloma (MM) patients.METHODS:Eighteen patients with MM who have no cytomorphologic plasma cells and CyIg+ cells in PB demonstrated by anti-kappa and anti delta MoAbs using ABC method were involved in the present study, including 3 cases in phases I-II and 15 cases in phase III. The complementary determining region 3 (CDR3) of immunoglobulin heavy chain (IgH) gene was amplified by polymerase chain reaction (PCR). We further analysed the single strand conformation of the PCR products by single strand conformation polymorphism (SSCP) analysis to detect the mononuclear cells in PB and BM of the patients simultaneously.RESULTS:The same PCR products of IgH-CDR3 gene with BM samples were found in PB of 11 MM patients. The same PCR products and single strand conformation in both PB and BM were found in 9 cases.CONCLUSIONS:This study has proved the presence of identical clonal malignant cells in PB and BM of MM patients. B cells are involved in the pathogenesis of MM.
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Sheri Skerget,Daniel Penaherrera,Ajai Chari,Sundar Jagannath,David S. Siegel,Ravi Vij,Gregory Orloff,Andrzej Jakubowiak,Ruben Niesvizky,Darla Liles,Jesus Berdeja,Moshe Levy,Jeffrey Wolf,Saad Z. Usmani,The MMRF CoMMpass Network,Robert Rifkin,Kenneth Meehan,Don Benson,Jeffrey Zonder,Joao Ascensao,Cristina Gasparetto,Miguel Hernández,Suzanne Trudel,Shaker Dakhil,Nizar Bahlis,Juan Vazquez Paganini,Pablo Rios,Antonia Sampol,Siva Mannem,Rebecca Silbermann,Matthew Lunning,Michael Chu,Carter Milner,Allyson Harroff,Mark Graham,Spencer Shao,Jyothi Dodlapati,Carlos Fernández de Larrea,Leonard Klein,Charles Kuzma,Rafael Fonseca,Gemma Azaceta,Miquel Granell,Carmen Martinez-Chamorro,Rama Balaraman,Carlos Silva,Anabelle Chinea,Caitlin Costello,Suman Kambhampati,DeQuincy Lewis,Michael Grossbard,Kathleen Yost,Robert Robles,Michael Sebag,Wayne Harris,Justinian Ngaiza,Michael Bar,Marie Shieh,Fredrick Min,Adedayo Onitilo,Fabio Volterra,William Wachsman,Madhuri Yalamachili,Eugenia Abella,Larry Anderson,Joan Bargay,Hani Hassoun,Gerald Hsu,Hakan Kaya,Alex Menter,Dilip Patel,Donald Richards,William Solomon,Robert Anderson,Sumeet Chandra,Miguel Conde,Saulias Girnius,May Matkiwsky,Isabel Krsnik,Shaji Kumar,Albert Oriol,Paula Rodríguez,Vivek Roy,Shanti Srinivas,Ronald Steis,Austin W. Christofferson,Sara Nasser,Jessica L. Aldrich,Christophe Legendre,Brooks Benard,Chase Miller,Bryce Turner,Ahmet Kurdoglu,Megan Washington,Venkata Yellapantula,Jonathan R. Adkins,Lori Cuyugan,Martin Boateng,Adrienne Helland,Shari Kyman,Jackie McDonald,Rebecca Reiman,Kristi Stephenson,Erica Tassone,Alex Blanski,Brianne Livermore,Meghan Kirchhoff,Daniel C. Rohrer,Mattia D'Agostino,Manuela Gamella,Kimberly Collison,Jennifer Stumph,Pam Kidd,Andrea Donnelly,Barbara Zaugg,Maureen Toone,Kyle McBride,Mary DeRome,Jennifer Rogers,David Craig,Winnie S. Liang,Norma C. Gutierrez,Scott D. Jewell,John Carpten,Kenneth C. Anderson,Hearn Jay Cho,Daniel Auclair,Sagar Lonial,Jonathan J. Keats

DOI: https://doi.org/10.1038/s41588-024-01853-0

IF: 30.8

2024-08-21

Nature Genetics

Abstract:Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The Multiple Myeloma Research Foundation's Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile study (NCT01454297) is a longitudinal, observational clinical study of newly diagnosed patients with multiple myeloma ( n = 1,143) where tumor samples are characterized using whole-genome sequencing, whole-exome sequencing and RNA sequencing at diagnosis and progression, and clinical data are collected every 3 months. Analyses of the baseline cohort identified genes that are the target of recurrent gain-of-function and loss-of-function events. Consensus clustering identified 8 and 12 unique copy number and expression subtypes of myeloma, respectively, identifying high-risk genetic subtypes and elucidating many of the molecular underpinnings of these unique biological groups. Analysis of serial samples showed that 25.5% of patients transition to a high-risk expression subtype at progression. We observed robust expression of immunotherapy targets in this subtype, suggesting a potential therapeutic option.

genetics & heredity
Validation of Next Generation Sequencing-Based Clonality Assays for Diagnosis and Minimal Residual Disease Tracking in Lymphoid Malignancies

Haiyan Wu,Feng Li,Jiacheng Cai,Ke Zhang,Xin Zheng,Jicheng Yao,Weifeng Wang,Kai Wang

DOI: https://doi.org/10.1182/blood-2021-150151

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Introduction: B or T cell receptor (BCR/TCR) clonal rearrangements have served as important diagnostic markers and minimal residual disease (MRD) tracking markers to guide treatment decisions in lymphoid malignancies. Next generation sequencing (NGS)-based BCR/TCR clonality assessment allows easier sample preparation, higher sensitivity and simpler standardization than flow cytometry and polymerase chain reaction (PCR)-based assays. Here, we developed NGS-based BCR/TCR clonality assays to identify and track disease-associated clonotypes of IGH, IGK, IGL, TCRB and TCRG rearrangements and BCL1/2-IGH translocations in lymphoid malignant cells. Our studies validated the analytical performance of the assays using genomic DNA (gDNA) from cell lines and patient samples diagnosed with acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), lymphoma and lymphoid blast phase chronic myeloid leukemia (BP-CML), as well as peripheral blood gDNA and circulating tumor DNA (ctDNA) from lymphoma patients. Methods: Our BCR/TCR clonality assays were based on two rounds of multiplex PCR followed by NGS. In the first-round PCR, the sequences of complementary determining region 3 (CDR3) in rearranged immune receptor genes were amplified by multiplex primers, and sample-specific index and NGS adapters were then added in the second-round PCR. Sequencing was performed on NovaSeq 6000 System and processed with customized bioinformatics pipelines. BCR clonality assays could identify IGH (V H-D H-J H or D H-J H), IGK (V κ-J κ, V κ-Kde and intronRSS-Kde) and IGL (V λ-J λ) rearrangements, as well as BCL1-IGH and BCL2-IGH translocations. TCR clonality assays could detect TCRB (V β-D β-J β) and TCRG (V γ-J γ) rearrangements. To evaluate the performance of our assays, we detected BCR or TCR clonality in gDNA from 4 cell lines and 40 clinical samples with ALL, MM, CLL and lymphoma, as well as paired chronic- and blast-phase samples of CML. Limit-of-detection (LOD) was estimated by clinical samples and cell lines with a background of peripheral blood gDNA from healthy donors. Linearity of detection was established with gDNA of cell lines spiked into normal gDNA to generate across orders of magnitude of clonal frequencies. To ensure consistent performance of the assays, we tested separate reactions and a single mixed reaction for IGH VDJ, IGH DJ, IGK and IGL. In addition, peripheral blood gDNA matching aforementioned lymphoma cases and ctDNA samples were also tested by our assays. Results: Both BCR clonality of B-cell lymphoid malignancies (B-ALL, MM, CLL and lymphoma) and TCR clonality of T-cell lymphoid malignancies (T-ALL and lymphoma) showed above 90% positive detection rate and mostly positive in more than one receptor gene. Chronic and blast phase samples from the same CML patient showed an identical dominant clonotype. The assays had high sensitivity, with LoD defined between 1 to 2 malignant cells in both BCR and TCR clonality assessment. Linearity was observed with clonal frequencies from 1 to 10 -6, which indicated consistence between observed and expected frequencies. The sequencing results with a single adjusted mixed reaction for IGH VDJ, IGH DJ, IGK and IGL were comparable to that with separate reactions, suitable for both diagnosed samples and MRD samples, suggesting the robustness of the assays. Our testing results also showed that peripheral blood gDNA of lymphoma patients carried identical clonotypes found in malignant tissues and ctDNA. Conclusion: We characterized and validated the performance of our NGS -based BCR/TCR clonality assays. We also demonstrated its potential application as a highly sensitive tool for diagnosis and MRD tracking for lymphoid malignancies, including ALL, MM, CLL, lymphoma and even CML at risk of lymphoid blast transformation. Disclosures No relevant conflicts of interest to declare.

hematology
The Detection of the Immunophenotyping of Plasma Cells in Patients with Multiple Myeloma

Jian Ouyang,Ermin Li,Min Zhou,Junhao Chen,Yangquan Xia,Xuejing Xu,Xian Wang,Rong-Fu Zhou

DOI: https://doi.org/10.1182/blood.v122.21.5335.5335

IF: 20.3

2013-01-01

Blood

Abstract:Abstract Objectives To study the immunophenotyping of plasma cells in patients with Multiple Myeloma(MM). To explore the antigen combination used to identify benign plasma cells from malignant plasma cells. Method Four-color flow cytometry (BD FACSCalibur )was respectively used to detect antigens expression rate of 44 diagnosed patients with MM and 25 normal controls (14 patients with nutritional iron deficiency anemia and 11 healthy bone marrow donators). The results were analyzed by the software of CellQuest. The positive expression rate of clusters of differentiation in cells surface is greater than twenty percent. Results The frequency of expression rate of clusters of differentiation among patients with MM are as fellows:CD138+(97.72%) ACD38+(100.00%) ACD56+(63.64%) ACD19-(84.09%) ACD20+(11.63%) ACD200+(77.27%) ACD28+(38.64%) ACD86+(54.55%). The frequency of expression rate among normal plasma cells of controls are CD138+(100.00%) ACD38+(100.00%) ACD56-(0.00%) ACD19+(96.00%) ACD20-(0.00%) ACD200+(0%) ACD28+(0.00%) ACD86+(4.00%). Conclusions Using the antigen combination of CD138 ACD38 ACD56 ACD19 ACD20 ACD200 ACD28 ACD86 is availably conducive to detect the phenotype of the malignant plasma cells of the patients with MM. Disclosures: No relevant conflicts of interest to declare.
Tumour-intrinsic features shape T-cell differentiation through myeloma disease evolution

Kane A Foster,Elise Rees,Louise Ainley,Eileen M Boyle,Lydia Lee,Gwennan Ward,Daria Galas-Filipowicz,Anna Mikolajczak,Emma J Lyon,Dylan Jankovic,Jasmine Rahman,Mahima Turakhia,Imran Uddin,Gordon Beattie,Yvette Hoade,Catherine Zhu,James L Reading,Ieuan G Walker,Michael A Chapman,Karthik Ramasamy,Javier Herrero,Benny Chain,Sergio A Quezada,Kwee Yong

DOI: https://doi.org/10.1101/2024.06.22.24309250

2024-07-12

Abstract:The haematological malignancy multiple myeloma is associated with skewed T-cell activation and function. T-cell alterations are detectable in asymptomatic myeloma precursor conditions and have the potential to identify precursor patients at imminent risk of progression. However, what myeloma-associated T-cells alterations represent mechanistically, how they relate to tumour burden and gene expression, and what influences high inter-patient variability in immune composition remains unknown. Here, we assembled the largest ever dataset of published and newly-generated single-cell RNA and TCR sequencing of the marrow and blood from patients with myeloma, precursor conditions, and age-matched non-cancer controls. We show myeloma is not associated with T-cell exhaustion and instead defined by a pattern of T-cell differentiation resembling antigen-driven terminal memory differentiation. Myeloma-associated T-cell differentiation was dependent on tumour-intrinsic features including tumour burden and tumour expression of antigen-presentation genes. Expanded TCR clones accumulating in myeloma were not enriched for viral specificity and were detected in effector states in highly infiltrated marrows. Together, these results suggest anti-tumour immunity drives a novel form of cancer-associated T-cell memory differentiation in myeloma.
Peripheral Blood Single-Cell Genotyping and Phenotyping in Multiple Myeloma Reveals Shared Mutations across Multiple Hematopoietic Cell Lineages

David G. Coffey,Aditi Agrawal,Maurizio Morri,Edus H. Warren,Robert Durruthy-Durruthy,Marc Arribas-Layton,Yue Wang,Norma F. Neff

DOI: https://doi.org/10.1182/blood-2021-154531

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Background: Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. While most genomic studies of the disease have focused on characterizing isolated bone marrow plasma cells, few have addressed somatic mutations within the immune microenvironment. We previously demonstrated that somatic mutations are significantly more numerous in unsorted blood compared to bone marrow and that the number of mutations correlated with elevated markers of disease. We also reported that genes implicated in clonal hematopoiesis of indeterminate potential (CHIP) are commonly mutated in the blood from patients with MM. Aim: To integrate single-cell DNA mutation analysis and protein expression to map the clonal relationship between circulating plasma cells and non-plasma cells within the peripheral blood of patients with MM. Methods: Although bulk DNA sequencing can estimate clonal heterogeneity using analytic deconvolution techniques, it is unable to distinguish which mutations occur in the same clone(s) nor can it correlate genotype with immunophenotype from the same cell. To accurately describe the clonal architecture of the blood, we combined targeted single-cell DNA sequencing (scDNA-seq) coupled with protein expression to define mutations specific to cell phenotypes using the Tapestri Platform (Mission Bio). For this analysis, we developed a custom amplicon panel covering 22 frequently mutated genes in MM and/or CHIP to perform scDNA-seq and 4 antibodies targeting CD138, CD19, CD3, and CD33 for immunophenotyping or plasma cells, B cells, T cells, and myeloid cells respectively. Results: Peripheral blood mononuclear cells were isolated from 17 blood samples collected from 12 patients with MM. Three samples were collected at diagnosis before treatment, 8 were collected post-treatment during remission, and 6 were collected at relapse. Serial samples were obtained before and after autologous stem cell transplant from 4 patients. A total of 85,262 cells were sequenced uncovering 154 unique variants in 22 genes after quality filtering. There were 47 somatic variants, defined as those present in less than 40% of cells per sample. There were 52,136 total clones, defined as cells with identical genotypes, within this heterogenous population of cells. The most common non-synonymous somatic mutations were identified in genes SETD2, KMT2C, PPM1D. An immunophenotype was assigned to 82% of cells according to the protein with the most abundant number of reads. Dimensionality reduction of single-cell genotype using t-distributed stochastic neighbor embedding (t-SNE) effectively clustered cells according to sample and by patient in cases where there were multiple samples from the same individual. Patients with active myeloma and known circulating plasma cells detected by clinical flow cytometry were found to have the greatest proportion of CD138+ cells as well as the highest mutational burden. It was rare to detect the same clone in two separate samples collected from the same patient at different time points (median time be collection was 248 days) which may be due to under-sampling or clonal evolution. Surprisingly, all somatic variants detected in plasma cells, were also present in other cell types suggesting they were acquired from a common progenitor cell rather than after differentiation. Conclusions: scDNA-seq coupled with immunophenotyping of the peripheral blood of patients with MM reveals somatic variants are shared across multiple hematopoietic cell lineages including plasma cells indicating these mutational are acquired from a common progenitor. Disclosures Durruthy-Durruthy: Mission Bio Inc.: Current Employment. Arribas-Layton: Mission Bio, Inc.: Current Employment. Wang: Mission Bio, Inc: Current Employment.

hematology
Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow

James Favaloro,Christian E. Bryant,Edward Abadir,Samuel Gardiner,Shihong Yang,Tracy King,Najah Nassif,Bronwyn A. O’Brien,Lisa M. Sedger,Richard Boyle,Douglas E. Joshua,Joy Ho P.

DOI: https://doi.org/10.3324/haematol.2024.285952

2024-10-05

Haematologica

Abstract:Not available. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

hematology
Clonal Heterogeneityand Evolutional Paths in Multiple Myeloma Revealed By QM-FISH in Single Cell of Sequential Analysis

Xiaoqi Qin,Gang An,Yu Qin,Yan Xu,Xiaoyan Feng,Meirong Zang,Weiwei Sui,Shuhui Deng,Shuhua Yi,Wen Zhou,Lugui Qiu

DOI: https://doi.org/10.1182/blood.v124.21.3395.3395

IF: 20.3

2014-12-06

Blood

Abstract:Abstract Background: Clonal heterogeneity is a hallmark of many solid and hematologic malignancies. Clonal heterogeneity may foster clonal evolution and affect personalized care strategies in multiple myeloma(MM). In order to grasp this ubiquitous phenomenon and its effect on MM patients’ prognosis, we report on sequential analysis by quantitative multicolor-fluorescence in situ hybridization (QM-FISH) in single cell of myeloma patients who were longitudinally followed. Methods: Bacterial artificial chromosomes (BAC) clones that contain target genes including TP53, Rb1, CKS1B, CYLD and cIAP, which belonged to secondary genetic variation of MM and were searched in the data base UCSC Genome Bioinformatics. Multicolor FISH probes were prepared by linking fluorescein labeled dUTP and dCTP to target genes by nick translation. We performed QM-FISH in single cell of 42 specimen from 17 myeloma patients who were longitudinally followed and compared the difference between myeloma patients at initial diagnosis and progression of disease. Results: Sequential samples revealed that MM may follow three clonal evolution patterns in the course of disease progression. In these 17 patients, myeloma clone in 5 patients had no changes over the time, 6 patients acquired one or more molecular abnormalities and only one predominant clone over the course, 6 patients had more than 1 clone in the course and all clones competing and tiding, or acquired one or more molecular abnormalities resulted in new clones emerging and all involved clones waxing and waning. Furthermore, we analyzed clone architecture in samples at initial diagnosis and 15/17(88.2%) cases had multiple subclones architecture at initial diagnosis. 3 patients of the first group (3/5, 60%) had more than 1 subclone, and all patients of the latter two groups had multiple subclones at initial time. Clonal heterogeneity may contribute to clonal evolution Conclusions: The outcome of tracking clonal heterogeneity and evolutional paths by QM-FISH is effective and feasible. Myeloma patients may follow 1 of 3 pathways to progress. Clonal heterogeneitymay foster lonal evolution in the course of disease progression. Disclosures No relevant conflicts of interest to declare.

hematology
The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma

Sarah Sandmann,Katharina Karsch,Peter Bartel,Rita Exeler,Tobias J. Brix,Elias K. Mai,Julian Varghese,Georg Lenz,Cyrus Khandanpour

DOI: https://doi.org/10.3389/fonc.2022.919278

IF: 4.7

2022-07-19

Frontiers in Oncology

Abstract:Introduction: A variety of biomarkers are considered for diagnosis (e.g., β2-microgobulin, albumin, or LDH) and prognosis [e.g., cytogenetic aberrations detected by fluorescence in situ hybridization (FISH)] of multiple myeloma (MM). More recently, clonal evolution has been established as key. Little is known on the clinical implications of clonal evolution. Methods: We performed in-depth analyses of 25 patients with newly diagnosed MM with respect to detailed clinical information analyzing blood samples collected at several time points during follow-up (median follow-up: 3.26 years since first diagnosis). We split our cohort into two subgroups: with and without new FISH clones developing in the course of disease. Results: Each subgroup showed a characteristic chromosomal profile. Forty-three percent of patients had evidence of appearing new clones. The patients with new clones showed an increased number of translocations affecting chromosomes 14 (78% vs. 33%; p = 0.0805) and 11, and alterations in chromosome 4 (amplifications and translocations). New clones, on the contrary, were characterized by alterations affecting chromosome 17. Subsequent to the development of the new clone, 6 out of 9 patients experienced disease progression compared to 3 out of 12 for patients without new clones. Duration of the therapy applied for the longest time was significantly shorter within the group of patients developing new clones (median: 273 vs. 406.5 days; p = 0.0465). Discussion: We demonstrated that the development of new clones, carrying large-scale alterations, was associated with inferior disease course and shorter response to therapy, possibly affecting progression-free survival and overall survival as well. Further studies evaluating larger cohorts are necessary for the validation of our results.

oncology
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Guy Ledergor,Assaf Weiner,Mor Zada,Shuang-Yin Wang,Yael C. Cohen,Moshe E. Gatt,Nimrod Snir,Hila Magen,Maya Koren-Michowitz,Katrin Herzog-Tzarfati,Hadas Keren-Shaul,Chamutal Bornstein,Ron Rotkopf,Ido Yofe,Eyal David,Venkata Yellapantula,Sigalit Kay,Moshe Salai,Dina Ben Yehuda,Arnon Nagler,Lev Shvidel,Avi Orr-Urtreger,Keren Bahar Halpern,Shalev Itzkovitz,Ola Landgren,Jesus San-Miguel,Bruno Paiva,Jonathan J. Keats,Elli Papaemmanuil,Irit Avivi,Gabriel I. Barbash,Amos Tanay,Ido Amit

DOI: https://doi.org/10.1038/s41591-018-0269-2

IF: 82.9

2018-12-01

Nature Medicine

Abstract:Multiple myeloma, a plasma cell malignancy, is the second most common blood cancer. Despite extensive research, disease heterogeneity is poorly characterized, hampering efforts for early diagnosis and improved treatments. Here, we apply single cell RNA sequencing to study the heterogeneity of 40 individuals along the multiple myeloma progression spectrum, including 11 healthy controls, demonstrating high interindividual variability that can be explained by expression of known multiple myeloma drivers and additional putative factors. We identify extensive subclonal structures for 10 of 29 individuals with multiple myeloma. In asymptomatic individuals with early disease and in those with minimal residual disease post-treatment, we detect rare tumor plasma cells with molecular characteristics similar to those of active myeloma, with possible implications for personalized therapies. Single cell analysis of rare circulating tumor cells allows for accurate liquid biopsy and detection of malignant plasma cells, which reflect bone marrow disease. Our work establishes single cell RNA sequencing for dissecting blood malignancies and devising detailed molecular characterization of tumor cells in symptomatic and asymptomatic patients.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Abstract 7663: Identification of high-risk patients in multiple myeloma using a clonal gene signature

Jian-Rong Li,Christiana Wang,Chao Cheng

DOI: https://doi.org/10.1158/1538-7445.am2024-7663

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Introduction: Multiple myeloma (MM) is a heterogeneous disease with a small subset of high-risk patients associated with poor prognosis. The identification of these patients is crucial for treatment management and strategic decisions. Methods: We developed a novel computational framework that only requires gene expression profiles to define prognostic gene signatures by selecting genes with expression driven by inferred clonal copy number alterations. We applied this framework to MM and developed a clonal gene signature (CGS) consisting of only 22 genes. This prognostic signature was evaluated in 5 independent datasets with gene expression data of a total of 2,155 MM samples. For each patient, we calculated a prognostic score based on the expression of the signature genes. Multivariate Cox regression analyses were performed to investigate the association of these signature scores with patient prognosis after adjusting established clinical factors. The performances of CGS and the only commercialized MM gene signatures, GEP70 and SKY92, in identifying high-risk patients were carefully compared by multiple different approaches. Results: Our results indicated that CGS provided significant prognostic values after adjusting for well-established prognostic factors including cytogenetic abnormalities, International Staging System (ISS), and Revised ISS (R-ISS). In addition, it showed significant prognostic associations in patient subsets stratified by these conventional prognostic factors. Importantly, CGS demonstrated a better performance in identifying high-risk patients compared to the GEP70 and SKY92 signatures, which have been recommended for prognostic stratification in MM. Moreover, CGS can further stratify patients into subgroups with significantly differential prognoses when applied to the high-risk and low-risk groups already identified by GEP70 and SKY92. The higher CGS score of patients is significantly associated with poor response to dexamethasone, a commonly used drug for MM treatment. Conclusions: In summary, we proposed a computational framework that only requires gene expression data to identify clonal gene signatures for prognosis prediction. The CGS provides a useful biomarker for improving prognostic stratification in MM, especially for the identification of patients with the highest risk. The computational framework used for defining this signature provides a useful tool, which can be readily applied to many other cancer types. Citation Format: Jian-Rong Li, Christiana Wang, Chao Cheng. Identification of high-risk patients in multiple myeloma using a clonal gene signature [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7663.

oncology
Study of Immunoglobulin and T-cell Receptor Gene Rearrangements in Patients with Non-Hodgkin' S Lymphoma

Ruo-qi Wu,Chun Qiao,Yi Tong,Zheng Ge,Jian-fu Zhang,Yu-Jie Wu,Hai-rong Qiu,Zhi Wang,Peng Liu

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2012.01.003

2012-01-01

Abstract:OBJECTIVE:To investigate immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements in bone marrow or peripheral blood of patients with non-Hodgkin's lymphoma (NHL), and to explore the potential clinical significance.METHODS:The Ig/TCR gene rearrangements in bone marrow or peripheral blood of 139 NHL patients were analyzed by using BIOMED-2 multiple primers system and Multiplex PCR assay.RESULTS:Ig clonality was detected in 85.4% (70/82) of chronic lymphocytic leukemia (CLL), including 46.3% (38/82) IgH rearrangement, 62.2% (51/82) IgK rearrangement and 1.2% (1/82) IgL rearrangement, and in 39.4% (13/33) of other categories of B-lineage NHL (B-NHL), including 33.3% (11/33) IgH and 39.4% (13/33) IgK rearrangements. TCR clonality was detected in 50.0% (12/24) of all definite T-lineage NHL (T-NHL), including 8.3% (2/24) TCRB and 45.8% (11/24) TCRG, no TCRD was detected. The detection rate of gene rearrangements of NHL diversed in different clinical stages \[36.4% in early stage (Ann Arbor stage I and II) and 45.6% in late stage (III and IV)\] and in different degrees of malignancy (40.0% indolent NHL and 45.6% aggressive NHL), but no obvious statistical significance was obtained (P > 0.05). The detection rate of bone marrow invasions of NHL (except CLL) with examinations of bone marrow smear under the microscope was 12.3% (7/57), much lower than the clonality testing (43.9%, 25/57) (P < 0.05). Sensitivity test showed that the sensitivity of malignant clonality testing by multiplex PCR was 3.12% - 6.25%.CONCLUSIONS:The detection rate of gene rearrangements diverses in different clinical stages and degrees of malignancy of NHL, but the correlation has not been proved in this research. The sensitivity of multiplex PCR-based clonality testing is enhanced with the combination of BIOMED-2 primers system. It is more sensitive than the morphological examinations of bone marrow smear in detecting bone marrow invasions, and may provide a powerful strategy in the routine diagnosis and assessment after treatment.
Genotypic identification of polyclonal plasma cells in plasma cell dyscrasias shows an aberrant single-cell phenotype with clinical implications

Matteo Claudio Da Vià,Francesca Lazzaroni,Antonio Matera,Alessio Marella,Akihiro Maeda,Claudio De Magistris,Loredana Pettine,Sonia Fabris,Stefania Pioggia,Alfredo Marchetti,Marzia Barbieri,Silvia Lonati,Alessandra Cattaneo,Marta Tornese,Margherita Scopetti,Nayyer Latifinavid,Giancarlo Castellano,Federica Torricelli,Antonino Neri,Cathelijne Fokkema,Tom Cupedo,Marta Lionetti,Francesco Passamonti,Niccolò Bolli

DOI: https://doi.org/10.1101/2024.05.26.595470

2024-05-27

Abstract:Multiple Myeloma (MM) is driven by clonal plasma cell (PC)-intrinsic factors and changes in the tumorigenic microenvironment (TME). To investigate if residual polyclonal PCs (pPCs) are disrupted, single-cell (sc) RNAseq and sc B-cell receptor analysis were applied in a cohort of 46 samples with PC dyscrasias and 18 healthy donors (HDs). Out of n=213,074 CD138pos PCs, 42,717 were genotypically identified as pPCs. Compared to HDs, we detected quantitative and qualitative differences in pPCs of patients showing immunoparesis, where we showed a pro-inflammatory status, driven by specific cellular interactions with TME. Finally, we derived a "hPC signature" that, once inferred in the CoMMpass dataset, was predictive of PFS and OS. Our findings show that genotypic, single-cell identification of pPCs in PC dyscrasias has relevant pathogenic and clinical implications.

Cancer Biology
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Mara John,Moutaz Helal,Johannes Duell,Greta Mattavelli,Emilia Stanojkovska,Nazia Afrin,Alexander Michael Leipold,Maximilian Johannes Steinhardt,Xiang Zhou,David Žihala,Anjana Anilkumar Sithara,Julia Mersi,Johannes M Waldschmidt,Christine Riedhammer,Sofie-Katrin Kadel,Marietta Truger,Rudolf A. Werner,Claudia Haferlach,Hermann Einsele,Kai Kretzschmar,Tomáš Jelínek,Andreas Rosenwald,K. Martin Kortüm,Angela Riedel,Leo Rasche

DOI: https://doi.org/10.1182/blood.2024024590

IF: 20.3

2024-08-24

Blood

Abstract:Extramedullary disease (EMD) is a high-risk feature of multiple myeloma (MM) and remains a poor prognostic factor even in the era of novel immunotherapies. Here we applied spatial transcriptomics (tomo-seq [n=2] and 10X Visium [n=12]), and single-cell RNA sequencing (scRNAseq [n=3]) to a set of 14 EMD biopsies to dissect the three-dimensional architecture of tumor cells and their microenvironment. Overall, the infiltrating immune and stromal cells showed both intra- and inter-patient variation...

hematology
Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones

Libere J. Ndacayisaba,Kate E. Rappard,Stephanie N. Shishido,Carmen Ruiz Velasco,Nicholas Matsumoto,Rafael Navarez,Guilin Tang,Pei Lin,Sonia M. Setayesh,Amin Naghdloo,Ching-Ju Hsu,Carlisle Maney,David Symer,Kelly Bethel,Kevin Kelly,Akil Merchant,Robert Orlowski,James Hicks,Jeremy Mason,Elisabeth E. Manasanch,Peter Kuhn

DOI: https://doi.org/10.3390/curroncol29050242

2022-04-21

Current Oncology

Abstract:Multiple myeloma is an incurable malignancy that initiates from a bone marrow resident clonal plasma cell and acquires successive mutational changes and genomic alterations, eventually resulting in tumor burden accumulation and end-organ damage. It has been recently recognized that myeloma secondary genomic events result in extensive sub-clonal heterogeneity both in localized bone marrow areas and circulating peripheral blood plasma cells. Rare genomic subclones, including myeloma initiating cells, could be the drivers of disease progression and recurrence. Additionally, evaluation of rare myeloma cells in blood for disease monitoring has numerous advantages over invasive bone marrow biopsies. To this end, an unbiased method for detecting rare cells and delineating their genomic makeup enables disease detection and monitoring in conditions with low abundant cancer cells. In this study, we applied an enrichment-free four-plex (CD138, CD56, CD45, DAPI) immunofluorescence assay and single-cell DNA sequencing for morphogenomic characterization of plasma cells to detect and delineate common and rare plasma cells and discriminate between normal and malignant plasma cells in paired blood and bone marrow aspirates from five patients with newly diagnosed myeloma (N = 4) and monoclonal gammopathy of undetermined significance (n = 1). Morphological analysis confirms CD138+CD56+ cells in the peripheral blood carry genomic alterations that are clonally identical to those in the bone marrow. A subset of altered CD138+CD56- cells are also found in the peripheral blood consistent with the known variability in CD56 expression as a marker of plasma cell malignancy. Bone marrow tumor clinical cytogenetics is highly correlated with the single-cell copy number alterations of the liquid biopsy rare cells. A subset of rare cells harbors genetic alterations not detected by standard clinical diagnostic methods of random localized bone marrow biopsies. This enrichment-free morphogenomic approach detects and characterizes rare cell populations derived from the liquid biopsies that are consistent with clinical diagnosis and have the potential to extend our understanding of subclonality at the single-cell level in this disease. Assay validation in larger patient cohorts has the potential to offer liquid biopsy for disease monitoring with similar or improved disease detection as traditional blind bone marrow biopsies.

oncology
The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence in Situ Hybridization in Multiple Myeloma

Gang An,Zengjun Li,Yu-Tzu Tai,Chirag Acharya,Qian Li,Xiaoqi Qin,Shuhua Yi,Yan Xu,Xiaoyan Feng,Chengwen Li,Jiawei Zhao,Lihui Shi,Meirong Zang,Shuhui Deng,Weiwei Sui,Mu Hao,Dehui Zou,Yaozhong Zhao,Junyuan Qi,Tao Cheng,Kun Ru,Jianxiang Wang,Kenneth C. Anderson,Lugui Qiu

DOI: https://doi.org/10.1158/1078-0432.ccr-14-2576

IF: 13.801

2015-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: Accumulating evidence indicates that intratumor heterogeneity is prevalent in multiple myeloma and that a collection of multiple, genetically distinct subclones are present within the myeloma cell population. It is not clear whether the size of clonal myeloma populations harboring unique cytogenetic abnormalities carry any additional prognostic value. Experimental Design: We analyzed the prognostic impact of cytogenetic aberrations by fluorescence in situ hybridization at different cutoff values in a cohort of 333 patients with newly diagnosed myeloma and 92 patients with relapsed myeloma. Results: We found that nearly all IgH-related arrangements were observed in a large majority of the purified plasma cells; however, 13q deletion, 17p deletion, and 1q21 amplification appeared in different percentages within the malignant plasma cell population. Based on the size of subclones carrying these cytogenetic aberrations, the patients were divided into four groups: 0%–10%, 10.5%–20%, 20.5%–50%, and >50%. Receiver-operating characteristics analysis was applied to determine the optimal cutoff value with the greatest differential survival and showed that the most powerful clone sizes were 10% for 13q deletion, 50% for 17p deletion, and 20% for 1q21 gains, which provided the best possible cutoffs for predicting poor outcomes. Conclusions: Our study indicated that the impact of clone size on prognostic value varies between specific genetic abnormalities. Prognostic value was observed for even a subgroup of plasma cells harboring the cytogenetic aberration of 13q deletion and 1q21 gains; however, 17p deletion displayed the most powerful cutoff for predicting survival only if the predominant clones harbored the abnormality. Clin Cancer Res; 21(9); 2148–56. ©2015 AACR.
Assessment of T-Cell Receptor Repertoire and Clonal Expansion in Peripheral T-Cell Lymphoma Using RNA-Seq Data

Chao Wang,Qiang Gong,Weiwei Zhang,Javeed Iqbal,Yang Hu,Timothy C. Greiner,Adam Cornish,Raul Rabadan,Francesco Abate,Xin Wang,Giorgio Inghirami,McKeithan W. Timothy,Wing C Chan

DOI: https://doi.org/10.1182/blood.v126.23.1451.1451

IF: 20.3

2015-01-01

Blood

Abstract:Introduction: Diversity of the T-cell receptor (TCR) repertoire reflects the initial V(D)J recombination events as shaped by selection by self and foreign antigens. Next generation sequencing is a powerful method for profiling the TCR repertoire, including sequences encoding complementarity-determining region 3 (CDR3). Peripheral T-cell lymphoma (PTCL) is a group of malignancies that originate from mature T-cells. T-cell clonality of PTCL is routinely evaluated with a PCR-based method to detect TCR gamma and less frequently beta chain rearrangements using genomic DNA. However, there are limitations with this approach, chief among which is the lack of sequence information. To date, the TCR repertoire of different subtypes of PTCL remains poorly defined.
Expanded T cell clones with lymphoma driver somatic mutations in refractory celiac disease

Mandeep Singh,Raymond H. Y. Louie,Jerome Samir,Matthew A. Field,Claire Milthorpe,Thiruni Aldiriki,Joseph Mackie,Ellise Roper,Megan Faulks,Katherine J. L. Jackson,Andrew Calcino,Melinda Y. Hardy,Piers Blombery,Timothy G. Amos,Ira W. Deveson,Scott A. Read,Dmitri Shek,Antoine Guerin,Cindy S Ma,Stuart G. Tangye,Antonio Di Sabatino,Marco V. Lenti,Alessandra Pasini,Rachele Ciccocioppo,Golo Ahlenstiel,Dan Suan,Jason A. Tye-Din,Christopher C. Goodnow,Fabio Luciani

DOI: https://doi.org/10.1101/2024.03.17.24304320

2024-03-22

Abstract:Intestinal inflammation continues in a subset of celiac disease (CD) patients despite a gluten-free diet. Here, by applying multiomic single cell analysis to duodenal biopsies, we find low-grade malignancies with lymphoma driver mutations in refractory CD type 2 (RCD2) patients comprise surface CD3 negative (sCD3-) lymphocytes stalled at an innate lymphoid cell (ILC) - progenitor T cell stage undergoing extensive recombination. In people with refractory CD type 1 (RCD1), who currently lack explanation, we discover sCD3+ T cells with lymphoma driver mutations forming large clones displaying inflammatory and cytotoxic molecular profiles in 6 of 10 individuals, and a single small clone in 1 of 4 active recently diagnosed CD cases. Accumulation of driver-mutated T cells and their sCD3-progenitors may explain chronic, non-responsive autoimmunity.

Allergy and Immunology
Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma

Yuting Yan,Xiaoqi Qin,Jiahui Liu,Huishou Fan,Lanting Liu,Zhen Yu,Shuhui Deng,Wei Liu,Dehui Zou,Lugui Qiu,Gang An

DOI: https://doi.org/10.1182/blood-2021-152794

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Single-cell analysis is of significant importance in delineate the exact phylogeny of subclonal population and in discovering subtle diversification. So far studies of intratumor heterogeneity and clonal evolution in multiple myeloma (MM) were largely focused at the bulk tumor population level. Here, we performed quantitative multi-gene fluorescence in situ hybridization (QM-FISH) in 129 longitudinal samples of 57 MM patients. All the patients had newly-diagnosed and relapsed paired samples. An expanded cohort of 188 MM patients underwent conventional FISH (cFISH) to validate the cytogenetic evolution in bulk tumor level. 43 of 57 patients (75.4%) harbored three or four cytogenetic clones at diagnosis. We delineated the phylogeny of subclonal tumor population and derived the evolutionary architecture in each patient.13q deletion and the first 1q gain tended to be earlier cytogenetic alternation, whereas 16q and 17p deletion were acquired later. Patients with clonal stabilization had a significantly improved OS than those with other evolutionary patterns (median OS, 71.2 vs. 39.7 vs. 35.2 vs. 25.5 months, for stable, differential, branching and linear patterns, respectively, p=0.001). Besides, a high degree of consistency and complementarity across QM-FISH and cFISH was observed in evaluation of cytogenetic evolution pattern in MM. In total, at least two time-point cytogenetic evaluations by cFISH were underwent in 188 MM patients. The proportion of patients with high-risk cytogenetic features was 33% at diagnosis and 49% at relapse. The prognostic value of the presence of high-risk aberrations at diagnosis were attenuated over time (HR=1.79, p=0.002 for survival from diagnosis; HR=1.55, p=0.026 for survival from relapse, ). Survival from relapse were greater influenced by the presence of high-risk aberrations at relapse (HR=2.07, figure 5E) rather than present at diagnosis (HR=1.55). The present study investigated the prognostic value of evolution in copy number or clone size of 1q21 gain/amplification during follow-up. The incidence of patients carrying at least three copies of 1q21 was higher after relapse than at diagnosis (69% vs. 55%, p=0.004).Patients were categorized as six groups according to the change patterns in copy number and clone size of 1q21 gain between the two time-point samplings. Patients without 1q21 gain/amplification at both time points (group B) and patients who had obvious decrease in clone size or loss of 1q21 gain at relapse (group A) experienced similar superior outcome (Failure free survival after relapse (2 nd FFS), 18.1 vs. 27.8 months, p=0.469), whereas patients carrying 1q21 gain/amplification at both time points with or without increase (group C,D) in clone size relatively worse survival (2 nd FFS 12.4 and 10.5 months, respectively, p<0.05 compare to group A and B). The remaining patients who had an increase in copy number of 1q21 and those who developed de novo 1q21 gain at relapse were observed poorest outcome (group E and F,2 nd FFS 6.7 and 8.9 months). The interval time between two time-point samplings were similar among groups, whereas the different evolution pattern of 1q21 gain could clearly stratify both overall survival and post-relapse survival (p<0.001). This study shows that QM-FISH is a valuable tool to elucidate the clonal architecture at single cell level. Clonal evolution pattern is of prognostic significance, highlighting the need for repeated cytogenetic evaluation in relapsed MM. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

hematology

Clonality detection of expanded T-cell populations in patients with multiple myeloma.

Analysis of Tumor Specific Immunoglobulin Gene Rearrangement in Peripheral Blood B-cells of Multiple Myeloma Patients by a PCR-SSCP Method.

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Validation of Next Generation Sequencing-Based Clonality Assays for Diagnosis and Minimal Residual Disease Tracking in Lymphoid Malignancies

The Detection of the Immunophenotyping of Plasma Cells in Patients with Multiple Myeloma

Tumour-intrinsic features shape T-cell differentiation through myeloma disease evolution

Peripheral Blood Single-Cell Genotyping and Phenotyping in Multiple Myeloma Reveals Shared Mutations across Multiple Hematopoietic Cell Lineages

Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow

Clonal Heterogeneityand Evolutional Paths in Multiple Myeloma Revealed By QM-FISH in Single Cell of Sequential Analysis

The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Abstract 7663: Identification of high-risk patients in multiple myeloma using a clonal gene signature

Study of Immunoglobulin and T-cell Receptor Gene Rearrangements in Patients with Non-Hodgkin' S Lymphoma

Genotypic identification of polyclonal plasma cells in plasma cell dyscrasias shows an aberrant single-cell phenotype with clinical implications

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones

The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence in Situ Hybridization in Multiple Myeloma

Assessment of T-Cell Receptor Repertoire and Clonal Expansion in Peripheral T-Cell Lymphoma Using RNA-Seq Data

Expanded T cell clones with lymphoma driver somatic mutations in refractory celiac disease

Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma